In This Article:
LUXEMBOURG, April 03, 2025--(BUSINESS WIRE)--Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (EUFI.PA, rated Baa3 by Moody’s and BBB- by Fitch, "Eurofins"), a global leader in bioanalytical testing, announces today the results of the tender offer (the "Tender Offer") in respect of its €400m 3.250% hybrid bond (ISIN: XS1716945586) issued on 13 November 2017 with a first call date on 13 November 2025 (the "2025 Hybrid Bond").
At the expiration deadline of the Tender Offer (2 April 2025, 5pm CEST), Eurofins had received valid tenders of €194m in aggregate principal amount of the 2025 Hybrid Bond.
Eurofins has decided to accept all valid tenders for purchase (all amounts in EUR):
| Current Outstanding | Bond Validly Tendered | Bond Accepted for | Remaining Outstanding |
| 400,000,000 | 193,978,000 | 193,978,000 | 206,022,000 |
Settlement of the purchase is expected to take place on 7 April 2025 (the "Settlement Date").
With this Tender Offer, together with the recent issuance of the new 2032 hybrid bond announced on last 27 March 2025, Eurofins has proactively managed the refinancing of its outstanding hybrid bonds.
Notes to Editors:
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins Scientific S.E. network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.
With ca. 63,000 staff across a decentralised and entrepreneurial network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.
Eurofins companies’ broad range of services are important for the health and safety of people and our planet. The ongoing investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our objective to provide our customers with high-quality services, innovative solutions and accurate results in the best possible turnaround time (TAT). Eurofins companies are well positioned to support clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the evolving requirements of healthcare practitioners around the world.